Aug. 18 at 12:05 PM
$SKYE at today's stock price, Punit's options are all under water, his 1m RSUs are only worth around
$400K (less than his annual salary) His success is clearly tied to a purchase/lease agreement for Nimacimab as a combo therapy drug. Industry leading safety profile, 30% efficacy as a combo and concentrated injection pen formulation with Aercor. The payoff is far from a guarantee but his long-term advisory position appears more likely to be outcome driven than phycological ploy.
